Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer Centre
Background Advanced biliary tract cancers (BTCs) carry a poor prognosis. Gemcitabine/platinum chemotherapy was the first-line standard until TOPAZ-1 and KEYNOTE-966 established immune checkpoint inhibitor-based combinations as a new standard. Real-world data with a chemotherapy-only comparator remain limited. Patients...